James M Joers1, Dinesh K Deelchand1, Tianmeng Lyu2, Uzay E Emir1,3, Diane Hutter1, Christopher M Gomez4, Khalaf O Bushara5, Lynn E Eberly2, Gülin Öz1. 1. Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN. 2. Division of Biostatistics, University of Minnesota, Minneapolis, MN. 3. School of Health Sciences, Purdue University, West Lafayette, IN. 4. Department of Neurology, University of Chicago, Chicago, IL. 5. Department of Neurology, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: To investigate whether early neurochemical abnormalities are detectable by high-field magnetic resonance spectroscopy (MRS) in individuals with spinocerebellar ataxias (SCAs) 1, 2, 3, and 6, including patients without manifestation of ataxia. METHODS: A cohort of 100 subjects (N = 18-21 in each SCA group, including premanifest mutation carriers; mean score on the Scale for the Assessment and Rating of Ataxia [SARA] <10 for all genotypes, and 22 matched controls) was scanned at 7 Tesla to obtain neurochemical profiles of the cerebellum and brainstem. A novel multivariate approach (distance-weighted discrimination) was used to combine regional profiles into an "MRS score." RESULTS: MRS scores robustly distinguished individuals with SCA from controls, with misclassification rates of 0% (SCA2), 2% (SCA3), 5% (SCA1), and 17% (SCA6). Premanifest mutation carriers with estimated disease onset within 10 years had MRS scores in the range of early-manifest SCA subjects. Levels of neuronal and glial markers significantly correlated with SARA and an Activities of Daily Living score in subjects with SCA. Regional neurochemical alterations were different between SCAs at comparable disease severity, with SCA2 displaying the most extensive neurochemical abnormalities, followed by SCA1, SCA3, and SCA6. INTERPRETATION: Neurochemical abnormalities are detectable in individuals before manifest disease, which may allow premanifest enrollment in future SCA trials. Correlations with ataxia and quality-of-life scores show that neurochemical levels can serve as clinically meaningful endpoints in trials. Ranking of SCA types by degree of neurochemical abnormalities indicates that the neurochemistry may reflect synaptic function or density. Ann Neurol 2018;83:816-829.
OBJECTIVE: To investigate whether early neurochemical abnormalities are detectable by high-field magnetic resonance spectroscopy (MRS) in individuals with spinocerebellar ataxias (SCAs) 1, 2, 3, and 6, including patients without manifestation of ataxia. METHODS: A cohort of 100 subjects (N = 18-21 in each SCA group, including premanifest mutation carriers; mean score on the Scale for the Assessment and Rating of Ataxia [SARA] <10 for all genotypes, and 22 matched controls) was scanned at 7 Tesla to obtain neurochemical profiles of the cerebellum and brainstem. A novel multivariate approach (distance-weighted discrimination) was used to combine regional profiles into an "MRS score." RESULTS: MRS scores robustly distinguished individuals with SCA from controls, with misclassification rates of 0% (SCA2), 2% (SCA3), 5% (SCA1), and 17% (SCA6). Premanifest mutation carriers with estimated disease onset within 10 years had MRS scores in the range of early-manifest SCA subjects. Levels of neuronal and glial markers significantly correlated with SARA and an Activities of Daily Living score in subjects with SCA. Regional neurochemical alterations were different between SCAs at comparable disease severity, with SCA2 displaying the most extensive neurochemical abnormalities, followed by SCA1, SCA3, and SCA6. INTERPRETATION: Neurochemical abnormalities are detectable in individuals before manifest disease, which may allow premanifest enrollment in future SCA trials. Correlations with ataxia and quality-of-life scores show that neurochemical levels can serve as clinically meaningful endpoints in trials. Ranking of SCA types by degree of neurochemical abnormalities indicates that the neurochemistry may reflect synaptic function or density. Ann Neurol 2018;83:816-829.
Authors: J Storm-Mathisen; N C Danbolt; F Rothe; R Torp; N Zhang; J E Aas; B I Kanner; I Langmoen; O P Ottersen Journal: Prog Brain Res Date: 1992 Impact factor: 2.453
Authors: Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn Journal: Lancet Neurol Date: 2011-12-02 Impact factor: 44.182
Authors: M Mascalchi; M Tosetti; R Plasmati; M C Bianchi; C Tessa; F Salvi; M Frontali; F Valzania; C Bartolozzi; C A Tassinari Journal: Ann Neurol Date: 1998-02 Impact factor: 10.422
Authors: Kathrin Reetz; Ana S Costa; Shahram Mirzazade; Anna Lehmann; Agnes Juzek; Maria Rakowicz; Romana Boguslawska; Ludger Schöls; Christoph Linnemann; Caterina Mariotti; Marina Grisoli; Alexandra Dürr; Bart P van de Warrenburg; Dagmar Timmann; Massimo Pandolfo; Peter Bauer; Heike Jacobi; Till-Karsten Hauser; Thomas Klockgether; Jörg B Schulz Journal: Brain Date: 2013-02-18 Impact factor: 13.501
Authors: Heike Jacobi; Kathrin Reetz; Sophie Tezenas du Montcel; Peter Bauer; Caterina Mariotti; Lorenzo Nanetti; Maria Rakowicz; Anna Sulek; Alexandra Durr; Perrine Charles; Alessandro Filla; Antonella Antenora; Ludger Schöls; Julia Schicks; Jon Infante; Jun-Suk Kang; Dagmar Timmann; Roberto Di Fabio; Marcella Masciullo; Laszlo Baliko; Bela Melegh; Sylvia Boesch; Katrin Bürk; Annkathrin Peltz; Jörg B Schulz; Isabelle Dufaure-Garé; Thomas Klockgether Journal: Lancet Neurol Date: 2013-05-22 Impact factor: 44.182
Authors: Maya Patel; Charles J Isaacs; Lauren Seyer; Karlla Brigatti; Sarah Gelbard; Cassandra Strawser; Debbie Foerster; Julianna Shinnick; Kimberly Schadt; Eppie M Yiu; Martin B Delatycki; Susan Perlman; George R Wilmot; Theresa Zesiewicz; Katherine Mathews; Christopher M Gomez; Grace Yoon; Sub H Subramony; Alicia Brocht; Jennifer Farmer; David R Lynch Journal: Ann Clin Transl Neurol Date: 2016-07-25 Impact factor: 4.511
Authors: Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz Journal: J Inherit Metab Dis Date: 2019-12-17 Impact factor: 4.982
Authors: Maria do Carmo Costa; Maria Radzwion; Hayley S McLoughlin; Naila S Ashraf; Svetlana Fischer; Vikram G Shakkottai; Patrícia Maciel; Henry L Paulson; Gülin Öz Journal: Mov Disord Date: 2020-07-04 Impact factor: 10.338
Authors: Gülin Öz; Dinesh K Deelchand; Jannie P Wijnen; Vladimír Mlynárik; Lijing Xin; Ralf Mekle; Ralph Noeske; Tom W J Scheenen; Ivan Tkáč Journal: NMR Biomed Date: 2020-01-10 Impact factor: 4.044
Authors: Dinesh K Deelchand; James M Joers; Adarsh Ravishankar; Tianmeng Lyu; Uzay E Emir; Diane Hutter; Christopher M Gomez; Khalaf O Bushara; Christophe Lenglet; Lynn E Eberly; Gülin Öz Journal: Mov Disord Clin Pract Date: 2019-07-10
Authors: Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal Journal: Ann Clin Transl Neurol Date: 2021-05-21 Impact factor: 4.511
Authors: Jillian Friedrich; Holly B Kordasiewicz; Brennon O'Callaghan; Hillary P Handler; Carmen Wagener; Lisa Duvick; Eric E Swayze; Orion Rainwater; Bente Hofstra; Michael Benneyworth; Tessa Nichols-Meade; Praseuth Yang; Zhao Chen; Judit Perez Ortiz; H Brent Clark; Gülin Öz; Sarah Larson; Huda Y Zoghbi; Christine Henzler; Harry T Orr Journal: JCI Insight Date: 2018-11-02
Authors: David D Bushart; Annie J Zalon; Hongjiu Zhang; Logan M Morrison; Yuanfang Guan; Henry L Paulson; Vikram G Shakkottai; Hayley S McLoughlin Journal: Cerebellum Date: 2021-02 Impact factor: 3.847